Alyeska Investment Group L.P. Lowers Stake in Palvella Therapeutics, Inc. $PVLA

Key Points

• Alyeska Investment Group cut its Palvella Therapeutics stake by 98.8% in the second quarter, selling 177,699 shares and retaining 2,223 shares valued at approximately $340,000. Institutional investors collectively own 40.11% of PVLA.
• Palvella shares opened at $150.55, near their 52-week high of $161.38, while the company reported a quarterly loss of $1.52 per share—worse than analysts’ expected loss of $1.17.
• Analyst sentiment remains broadly positive, with a consensus “Buy” rating and an average price target of $209.14, despite one “Sell” rating and recent insider and institutional share sales.

Alyeska Investment Group L.P. decreased its position in shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report) by 98.8% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,223 shares of the company's stock after selling 177,699 shares during the period. Alyeska Investment Group L.P.'s holdings in Palvella Therapeutics were worth $340,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in PVLA. KBC Group NV bought a new stake in Palvella Therapeutics in the first quarter valued at approximately $28,000. Northwestern Mutual Wealth Management Co. bought a new position in shares of Palvella Therapeutics during the second quarter valued at about $35,000. Group One Trading LLC boosted its holdings in shares of Palvella Therapeutics by 151.5% during the fourth quarter. Group One Trading LLC now owns 332 shares of the company's stock worth $35,000 after purchasing an additional 200 shares during the period. Russell Investments Group Ltd. purchased a new position in Palvella Therapeutics during the 3rd quarter valued at about $36,000. Finally, Archer Investment Corp purchased a new stake in Palvella Therapeutics in the 2nd quarter worth approximately $69,000. Institutional investors own 40.11% of the company's stock.

Palvella Therapeutics Stock Performance

Shares of NASDAQ PVLA opened at $150.55 on Wednesday. The company has a market cap of $2.17 billion, a PE ratio of -31.17 and a beta of -0.25. The firm's 50 day moving average price is $147.32 and its 200-day moving average price is $128.25. Palvella Therapeutics, Inc. has a 52-week low of $50.82 and a 52-week high of $161.38.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported ($1.52) earnings per share for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.35). On average, analysts forecast that Palvella Therapeutics, Inc. will post -6.36 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, COO Kathleen Goin sold 4,302 shares of the company's stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $152.21, for a total value of $654,807.42. Following the completion of the transaction, the chief operating officer owned 2,154 shares of the company's stock, valued at approximately $327,860.34. This represents a 66.64% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 17.20% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on PVLA. Truist Financial set a $207.00 target price on shares of Palvella Therapeutics in a research note on Wednesday, August 5th. HC Wainwright restated a "buy" rating and issued a $270.00 target price on shares of Palvella Therapeutics in a research note on Wednesday, July 22nd. Weiss Ratings restated a "sell (d-)" rating on shares of Palvella Therapeutics in a research report on Monday, June 29th. Stephens reiterated an "overweight" rating and issued a $220.00 price target on shares of Palvella Therapeutics in a research note on Thursday, May 21st. Finally, Chardan Capital raised shares of Palvella Therapeutics to a "strong-buy" rating in a research report on Tuesday, July 28th. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Palvella Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $209.14.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc NASDAQ: PVLA is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella's pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source